SCHEMBL14157484

SCHEMBL14157484

[CH2]CCN(CC[CH2])C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 2/20 0.47
HDAC6 Q9UBN7 2/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC2 Q92769 2/20 0.37
SSTR4 P31391 1/20 0.35
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA7 P43166 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
HDAC3 O15379 1/20 0.31
NCOR2 Q9Y618 1/20 0.31
DGAT1 O75907 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28269329 0.92 CA14 (0.43) CA14HDAC6HDAC1HDAC2SSTR4
SCHEMBL27312324 0.90 CA14 (0.41) CA14HDAC6HDAC1HDAC2SSTR4
SCHEMBL15942130 0.85 CA14 (0.38) CA14HDAC6HDAC1HDAC2SSTR4
SCHEMBL29290727 0.85 CA14 (0.48) CA14CA12CA1CA7
SCHEMBL11421139 0.82 CA14 (0.59) CA14CA12CA1
SCHEMBL14157466 0.82 CA14 (0.42) CA14HDAC6HDAC1HDAC2SSTR4
SCHEMBL3414844 0.81 HDAC6 (0.36) CA14HDAC6HDAC1HDAC2CA12
SCHEMBL2608081 0.80 CA14 (0.49) CA14HDAC6HDAC1HDAC2SSTR4
SCHEMBL503444 0.80 CA14 (0.53) CA14HDAC6HDAC1HDAC2SSTR4
SCHEMBL28355374 0.80 CA14 (0.47) CA14HDAC6HDAC1HDAC2SSTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858974-B9 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORP (JP) 2022-07-20 EP disclosed
EP-3489220-B9 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORP (JP) 2021-11-10 EP disclosed
EP-3489220-B1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORP (JP) 2021-08-18 EP disclosed
US-11084779-B2 Cationic lipids for therapeutic agent delivery formulations NITTO DENKO CORPORATION (JP) 2021-08-10 US disclosed
US-10961181-B2 2021-03-30 US disclosed
US-20200199064-A1 CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORPORATION (JP) 2020-06-25 US disclosed
US-20200085957-A1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORPORATION (JP) 2020-03-19 US disclosed
US-10441659-B2 Lipids for therapeutic agent delivery formulations NITTO DENKO CORPORATION (JP) 2019-10-15 US disclosed
EP-2998289-B1 COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY NITTO DENKO CORP (JP) 2019-08-07 EP disclosed
EP-3489220-A1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS Nitto Denko Corporation (JP) 2019-05-29 EP disclosed
US-20170081663-A1 RETINOID-LIPID DRUG CARRIER NITTO DENKO CORPORATION (JP) 2017-03-23 US disclosed
EP-2998289-A1 COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY NITTO DENKO CORPORATION (JP) 2016-03-23 EP disclosed
EP-2718261-B1 COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY NITTO DENKO CORP (JP) 2016-02-24 EP disclosed
US-9011903-B2 Cationic lipids for therapeutic agent delivery formulations NITTO DENKO CORPORATION (JP) 2015-04-21 US disclosed
EP-2858974-A1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS Nitto Denko Corporation (JP) 2015-04-15 EP disclosed
EP-2718261-A2 COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY Nitto Denko Corporation (JP) 2014-04-16 EP disclosed
WO-2013185116-A1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS PAYNE JOSEPH E (US) 2013-12-12 WO disclosed
WO-2012170952-A9 COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY NITTO DENKO CORPORATION (JP) 2013-02-21 WO disclosed
US-20130022665-A1 CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORPORATION (JP) 2013-01-24 US disclosed
WO-2012170952-A2 COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY NITTO DENKO CORPORATION (JP) 2012-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130022665-A1 CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS SGMS1, SGMS2, S1PR3 CA14 1115/4885HDAC6 1140/4885HDAC1 613/4885
US-20200085957-A1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS LIPA, SGMS2, SGMS1 CA14 2130/4885HDAC6 940/4885HDAC1 2043/4885
US-20200199064-A1 CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS SGMS1, SGMS2, CERT1 CA14 1002/4885HDAC6 1576/4885HDAC1 841/4885
US-10441659-B2 Lipids for therapeutic agent delivery formulations LIPA, SGMS2, SGMS1 CA14 2130/4885HDAC6 940/4885HDAC1 2043/4885
US-20170081663-A1 RETINOID-LIPID DRUG CARRIER RXRA, RXRG, LRAT CA14 4224/4885HDAC6 1215/4885HDAC1 2109/4885
US-10961181-B2 DEGS1, SGMS1, C5 CA14 1018/4885HDAC6 3412/4885HDAC1 1882/4885
US-11084779-B2 Cationic lipids for therapeutic agent delivery formulations SGMS1, SGMS2, CERT1 CA14 1002/4885HDAC6 1576/4885HDAC1 841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.